Skip to main content
Erschienen in: International Journal of Clinical Oncology 5/2014

01.10.2014 | Original Article

Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma

verfasst von: Songfeng Wei, Ming Gao, Cui Zhao, Yi Pan, Haixin Li, Jian Li, Xiaolong Li

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

A decreased radioiodine uptake is associated with high recurrence rate and reduced survival in papillary thyroid carcinoma (PTC). Sodium iodide symporter (NIS) expression status in aggressive PTC variants is unknown.

Methods

NIS expression in conventional PTC and aggressive PTC variants such as tall cell variant (TCV) and diffuse sclerosing variant (DSPTC) was investigated using immunohistochemical detection.

Results

Patients having TCV and DSPTC were significantly more likely to have extrathyroidal extension and lymph nodes metastases (P < 0.05). Positive NIS staining was identified in 228 of 312 (73.1 %) patients with conventional PTC, 9 of 28 (32.1 %) patients with TCV and 12 of 30 (40.0 %) patients with DSPTC. NIS expression distinguished conventional PTC from TCV and DSPTC significantly (P < 0.01).

Conclusion

Due to their low NIS expression, TCV and DSPTC need higher cumulative doses of radioactive iodine therapy to improve their prognosis.
Literatur
1.
Zurück zum Zitat Rivera M, Ghossein RA, Schoder H et al (2008) Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 113:48–56PubMedCrossRef Rivera M, Ghossein RA, Schoder H et al (2008) Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 113:48–56PubMedCrossRef
2.
Zurück zum Zitat Mehta RS, Negin B, Popii V et al (2008) An aggressive radio-resistant papillary thyroid cancer. Clin Adv Hematol Oncol 6:761–767PubMed Mehta RS, Negin B, Popii V et al (2008) An aggressive radio-resistant papillary thyroid cancer. Clin Adv Hematol Oncol 6:761–767PubMed
3.
Zurück zum Zitat Kloos RT (2008) Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J Clin Endocrinol Metab 93:1519–1525PubMedCrossRef Kloos RT (2008) Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J Clin Endocrinol Metab 93:1519–1525PubMedCrossRef
4.
Zurück zum Zitat Dohan O, Carrasco N (2003) Advances in Na(+)/I(−) symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol 213:59–70PubMedCrossRef Dohan O, Carrasco N (2003) Advances in Na(+)/I(−) symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol 213:59–70PubMedCrossRef
5.
Zurück zum Zitat Castro MR, Bergert ER, Beito TG et al (1999) Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer. J Endocrinol 163:495–504PubMedCrossRef Castro MR, Bergert ER, Beito TG et al (1999) Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer. J Endocrinol 163:495–504PubMedCrossRef
6.
Zurück zum Zitat Falvo L, Giacomelli L, D’Andrea V et al (2006) Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg 72:438–444PubMed Falvo L, Giacomelli L, D’Andrea V et al (2006) Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg 72:438–444PubMed
7.
Zurück zum Zitat Gonzalez–Gonzalez R, Bologna-Molina R, Carreon-Burciaga RG et al (2011) Papillary thyroid carcinoma: differential diagnosis and prognostic values of its different variants: review of the literature. ISRN Oncol 2011:915925PubMedPubMedCentral Gonzalez–Gonzalez R, Bologna-Molina R, Carreon-Burciaga RG et al (2011) Papillary thyroid carcinoma: differential diagnosis and prognostic values of its different variants: review of the literature. ISRN Oncol 2011:915925PubMedPubMedCentral
8.
Zurück zum Zitat Chow SM, Chan JK, Law SC et al (2003) Diffuse sclerosing variant of papillary thyroid carcinoma–clinical features and outcome. Eur J Surg Oncol 29:446–449PubMedCrossRef Chow SM, Chan JK, Law SC et al (2003) Diffuse sclerosing variant of papillary thyroid carcinoma–clinical features and outcome. Eur J Surg Oncol 29:446–449PubMedCrossRef
9.
Zurück zum Zitat Silver CE, Owen RP, Rodrigo JP et al (2011) Aggressive variants of papillary thyroid carcinoma. Head Neck 33:1052–1059PubMedCrossRef Silver CE, Owen RP, Rodrigo JP et al (2011) Aggressive variants of papillary thyroid carcinoma. Head Neck 33:1052–1059PubMedCrossRef
10.
Zurück zum Zitat Hawk WA, Hazard JB (1976) The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q 43:207–215PubMedCrossRef Hawk WA, Hazard JB (1976) The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q 43:207–215PubMedCrossRef
11.
Zurück zum Zitat Stern Y, Medelia O, Feinmesser M et al (1996) Nuclear DNA content of the tall cell variant of papillary carcinoma of the thyroid gland. Ann Otol Rhinol Laryngol 105:713–715PubMedCrossRef Stern Y, Medelia O, Feinmesser M et al (1996) Nuclear DNA content of the tall cell variant of papillary carcinoma of the thyroid gland. Ann Otol Rhinol Laryngol 105:713–715PubMedCrossRef
12.
Zurück zum Zitat Kumarasinghe MP, Kollure SK (1996) An aggressive variant of papillary carcinoma of thyroid: the tall cell type. Ceylon Med J 41:25–27PubMed Kumarasinghe MP, Kollure SK (1996) An aggressive variant of papillary carcinoma of thyroid: the tall cell type. Ceylon Med J 41:25–27PubMed
13.
Zurück zum Zitat Lam AK, Lo CY (2006) Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol 13:176–181PubMedCrossRef Lam AK, Lo CY (2006) Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol 13:176–181PubMedCrossRef
14.
Zurück zum Zitat Mizukami Y, Nonomura A, Michigishi T et al (1990) Diffuse sclerosing variant of papillary carcinoma of the thyroid. Report of three cases. Acta Pathol Jpn 40:676–682PubMed Mizukami Y, Nonomura A, Michigishi T et al (1990) Diffuse sclerosing variant of papillary carcinoma of the thyroid. Report of three cases. Acta Pathol Jpn 40:676–682PubMed
15.
Zurück zum Zitat van den Brekel MW, Hekkenberg RJ, Asa SL et al (1997) Prognostic features in tall cell papillary carcinoma and insular thyroid carcinoma. Laryngoscope 107:254–259PubMedCrossRef van den Brekel MW, Hekkenberg RJ, Asa SL et al (1997) Prognostic features in tall cell papillary carcinoma and insular thyroid carcinoma. Laryngoscope 107:254–259PubMedCrossRef
16.
Zurück zum Zitat Martins-Filho R, Ward LS, Amorim BJ et al (2010) Cumulative doses of radioiodine in the treatment of differentiated thyroid carcinoma: knowing when to stop. Arq Bras Endocrinol Metabol 54:807–812PubMed Martins-Filho R, Ward LS, Amorim BJ et al (2010) Cumulative doses of radioiodine in the treatment of differentiated thyroid carcinoma: knowing when to stop. Arq Bras Endocrinol Metabol 54:807–812PubMed
17.
Zurück zum Zitat Albareda M, Puig-Domingo M, Wengrowicz S et al (1998) Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid. Thyroid 8:385–391PubMedCrossRef Albareda M, Puig-Domingo M, Wengrowicz S et al (1998) Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid. Thyroid 8:385–391PubMedCrossRef
18.
Zurück zum Zitat Morari EC, Marcello MA, Guilhen AC et al (2011) Use of sodium iodide symporter expression in differentiated thyroid carcinomas. Clin Endocrinol (Oxf) 75:247–254CrossRef Morari EC, Marcello MA, Guilhen AC et al (2011) Use of sodium iodide symporter expression in differentiated thyroid carcinomas. Clin Endocrinol (Oxf) 75:247–254CrossRef
19.
Zurück zum Zitat Castro MR, Bergert ER, Goellner JR et al (2001) Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab 86:5627–5632PubMedCrossRef Castro MR, Bergert ER, Goellner JR et al (2001) Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab 86:5627–5632PubMedCrossRef
20.
Zurück zum Zitat Ostrowski ML, Merino MJ (1996) Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. Am J Surg Pathol 20:964–974PubMedCrossRef Ostrowski ML, Merino MJ (1996) Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. Am J Surg Pathol 20:964–974PubMedCrossRef
21.
Zurück zum Zitat Ozaki O, Ito K, Mimura T et al (1996) Papillary carcinoma of the thyroid. Tall-cell variant with extensive lymphocyte infiltration. Am J Surg Pathol 20:695–698PubMedCrossRef Ozaki O, Ito K, Mimura T et al (1996) Papillary carcinoma of the thyroid. Tall-cell variant with extensive lymphocyte infiltration. Am J Surg Pathol 20:695–698PubMedCrossRef
Metadaten
Titel
Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma
verfasst von
Songfeng Wei
Ming Gao
Cui Zhao
Yi Pan
Haixin Li
Jian Li
Xiaolong Li
Publikationsdatum
01.10.2014
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 5/2014
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-013-0620-z

Weitere Artikel der Ausgabe 5/2014

International Journal of Clinical Oncology 5/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.